Mary E. Klein
YOU?
Author Swipe
View article: Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Abemaciclib induced changes in CD8+ TILs in individual patients
View article: Supplementary Figure S7 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S7 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
ANGPTL4 is the most widely expressed and highly enriched transcript in treated cells compared to untreated cells
View article: Supplementary Figure S8 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S8 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
ANGPTL4 is necessary to drive senescence in palbociclib treated A549 cells
View article: Supplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Relationship between CDH18 expression, MDM2 downregulation, and ANGPTL4 mRNA expression in patients treated with abemaciclib
View article: Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Abemaciclib induced changes in CD8+ TILs in individual patients
View article: Supplementary Table S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Association between clinical covariates and PFS
View article: Supplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Enforced expression of ANGPTL4 can induce stable growth arrest and SASP gene expression in A549 cells treated with palbociclib
View article: Supplementary Table S1 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S1 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Representativeness of Study Participants
View article: Supplementary Figure S14 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S14 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Abemaciclib induced changes in FOXP3+ TILs in individual patients
View article: Supplementary Figure S8 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S8 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
ANGPTL4 is necessary to drive senescence in palbociclib treated A549 cells
View article: Supplementary Figure S11 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S11 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Quantification of the Abemaciclib induced changes in CDKN2A expression in each patient
View article: Supplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Enforced expression of ANGPTL4 can induce stable growth arrest and SASP gene expression in A549 cells treated with palbociclib
View article: Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Purpose:We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans.Patients and Methods:We coordinated a fir…
View article: Supplementary Table S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Transcript changes relative to quiescence
View article: Supplementary Figure S10 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S10 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Increases in ANGPTL4 are not associated with palbociclib induced senescence in ER+ breast cancer cell lines
View article: Supplementary Table S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Sequences of primers and shRNAs used in this study
View article: Supplementary Figure S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Patient toxicities graded according to the National Cancer Institute's common terminology criteria for adverse events, version 4.0
View article: Supplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Relationship between CDH18 expression, MDM2 downregulation, and ANGPTL4 mRNA expression in patients treated with abemaciclib
View article: Supplementary Figure S13 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S13 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Quantification of the Abemaciclib induced changes in CD4+ TILs in each patient
View article: Supplementary Table S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Transcript changes relative to quiescence
View article: Supplementary Table S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Dose reductions in this study identified by individual patients
View article: Supplementary Figure S14 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S14 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Abemaciclib induced changes in FOXP3+ TILs in individual patients
View article: Supplementary Figure S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Metabolome profiles of LS8817tetONFMDM2 undergoing cell cycle exit and geroconversion
View article: Supplementary Figure S12 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S12 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Quantification of the Abemaciclib induced changes in ANGPTL4 expression in each patient
View article: Supplementary Table S6 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S6 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Common SASP profile transcripts used in this study
View article: Supplementary Figure S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Durable quiescence can be established in LS8817tetONFMDM2 cells
View article: Supplementary Figure S12 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S12 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Quantification of the Abemaciclib induced changes in ANGPTL4 expression in each patient
View article: Supplementary Figure S6 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S6 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Palbociclib does not induce DNA damage in senescent LS8817 cells
View article: Supplementary Figure S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Figure S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Effect of shRNA hairpins on geroconversion when introduced into quiescent DDLStetONFDM2 cells
View article: Supplementary Table S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Supplementary Table S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma Open
Sequences of primers and shRNAs used in this study